Gilead Sciences, Inc. (GILD) Stock Price & Analysis
Gilead Sciences, Inc. (GILD) fell 1.18% to USD 129.31 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
GILD last closed at USD 130.86; the session ranged USD 129.04–131.64 on volume of 5,304,616 shares. Market capitalization is $160.55B, with a 52-week range of USD 108.46–157.29 (NMS). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 129.31 |
|---|---|
| Change | ▼ 1.18% (down) |
| Previous Close | USD 130.86 |
| Open | USD 130.93 |
| Day Range | USD 129.04 – 131.64 |
| 52-Week Range | USD 108.46 – 157.29 |
| Volume | 5,304,616 shares |
| Market Cap | $160.55B |
| Exchange | NMS |
Technical Analysis (GILD)
Nexqual's technical model rates GILD "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.86 (neutral) |
| vs SMA50 | Below (USD 129.65) |
| MACD | 0.58 (positive) |
Analyst Ratings (GILD)
Wall Street analysts rate GILD "Buy" based on 27 analysts, with a mean price target of USD 157.56 (range USD 120–180), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 157.56 |
| High Target | USD 180 |
| Low Target | USD 120 |
| Buy / Hold / Sell | 22 / 7 / 0 |
Earnings (GILD)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -7.27 |
| Revenue Estimate | $7.40B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.03 vs est 1.91 ▲ beat |
| 2025-12-31 | USD 1.86 vs est 1.81 ▲ beat |
| 2025-09-30 | USD 2.47 vs est 2.14 ▲ beat |
| 2025-06-30 | USD 2.01 vs est 1.96 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (GILD)
| Total Revenue | $29.74B |
|---|---|
| Revenue Growth (YoY) | +4.40% |
| Gross Margin | +79.37% |
| Operating Margin | +39.28% |
| Profit Margin | +30.99% |
| ROE | +43.36% |
| Debt / Equity | 94.64 |
| Current Ratio | 1.97 |
| Total Cash | $9.82B |
| Total Debt | $22.17B |
| Free Cash Flow | $7.93B |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (GILD)
Nexqual rates Gilead Sciences, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Mixed — Revenue +2.4% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 79%, operating 39% |
| Balance Sheet | Mixed — $9.82B cash vs $22.2B debt |
| Cash Flow | Strong — FCF $7.93B, 27% margin |
| Efficiency | Strong — ROE 43%, ROA 13.3% |
Ownership (GILD)
| Insider Ownership | +0.12% |
|---|---|
| Institutional Ownership | +94.28% |
| Shares Outstanding | 1.24B |
| Float | 1.24B |
| Short % of Float | +2.05% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (GILD)
Gilead Sciences, Inc. is led by Daniel Patrick O'Day (age 60), Chairman & CEO, per Nexqual as of July 25, 2026 at 01:13 UTC.
| Chairman & CEO | Daniel Patrick O'Day (age 60) |
|---|---|
| Executive VP & CFO | Andrew D. Dickinson (age 55) |
| Senior Vice President of Treasury & Investor Relations | Jacquie Ross C.F.A. |
| Executive Vice President of Human Resources | Jyoti K. Mehra (age 48) |
| Senior Vice President of Research, Innovation & Portfolio | Linda Slanec Higgins (age 63) |
Major Backers & Investors (GILD)
Notable institutional backers of Gilead Sciences, Inc. include FMR, LLC, Capital Group, Invesco, according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 5.79% |
| Capital Group | 5.51% |
| Invesco | 5.47% |
| JPMorgan | 3.74% |
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 1.46% |
| Fidelity | 1.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.05% |
| BlackRock | 10.91% |
| State Street | 6.03% |
| Geode Capital | 2.39% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Gilead Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
- The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
- It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
- Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMGN | Amgen Inc. | USD 376.04 | ▲ 2.73% |
| BIIB | Biogen Inc. | USD 202.19 | ▲ 2.25% |
| ABBV | AbbVie Inc. | USD 259.36 | ▲ 2.39% |
| BMY | Bristol-Myers Squibb Company | USD 62.09 | ▲ 2.19% |
| REGN | Regeneron Pharmaceuticals, Inc. | USD 656.01 | ▲ 0.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.